drugset / Trial / NCT00962312

Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer

NCT00962312 ↗

Phase 2 Completed 9 enrolled Cancer Trials Ireland
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib ditosylate together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving lapatinib ditosylate together with capecitabine works in treating patients with metastatic pancreatic cancer.

Timeline

Start
2009-01
Primary completion
2010-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — Oral
Subject Lapatinib Small molecule — Oral